Tirzepatide

Name

CAS NO.

Purity

≥ 98%

Molecular formula

Formula Weight

4813

Packaging

1g，100g，1000g

Introduction

Tirzepatide is a novel dual-receptor agonist targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP, also known as gastric inhibitory peptide), administered once weekly. Both GLP-1 and GIP belong to the incretin family and are polypeptides secreted by the human gastrointestinal mucosa. GLP-1 binds to receptors on pancreatic islet cells and stimulates insulin secretion, thereby lowering blood sugar. It also delays gastric emptying and suppresses appetite, thus controlling weight. GIP inhibits gastric acid and pepsin secretion, stimulates insulin release, and inhibits gastric motility and emptying, complementing the effects of GLP-1 receptor agonists. Tirzepatide integrates two insulin-stimulating effects into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes.